Cargando…
P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621507/ http://dx.doi.org/10.1097/01.HS9.0000890764.00950.f2 |
| _version_ | 1784821572339499008 |
|---|---|
| author | Seifert, Nicole Reinke, Sarah Grund, Johanna Müller-Meinhard, Berit Engert, Andreas Bröckelmann, Paul J. Klapper, Wolfram Altenbuchinger, Michael |
| author_facet | Seifert, Nicole Reinke, Sarah Grund, Johanna Müller-Meinhard, Berit Engert, Andreas Bröckelmann, Paul J. Klapper, Wolfram Altenbuchinger, Michael |
| author_sort | Seifert, Nicole |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621507 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215072022-11-01 P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma Seifert, Nicole Reinke, Sarah Grund, Johanna Müller-Meinhard, Berit Engert, Andreas Bröckelmann, Paul J. Klapper, Wolfram Altenbuchinger, Michael Hemasphere Genomics, Biology & Microenvironment Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621507/ http://dx.doi.org/10.1097/01.HS9.0000890764.00950.f2 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Genomics, Biology & Microenvironment Seifert, Nicole Reinke, Sarah Grund, Johanna Müller-Meinhard, Berit Engert, Andreas Bröckelmann, Paul J. Klapper, Wolfram Altenbuchinger, Michael P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma |
| title | P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma |
| title_full | P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma |
| title_fullStr | P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma |
| title_full_unstemmed | P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma |
| title_short | P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma |
| title_sort | p049: reduced features of t-cell activation before and during anti-pd-1 treatment in classical hodgkin lymphoma |
| topic | Genomics, Biology & Microenvironment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621507/ http://dx.doi.org/10.1097/01.HS9.0000890764.00950.f2 |
| work_keys_str_mv | AT seifertnicole p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT reinkesarah p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT grundjohanna p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT mullermeinhardberit p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT engertandreas p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT brockelmannpaulj p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT klapperwolfram p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma AT altenbuchingermichael p049reducedfeaturesoftcellactivationbeforeandduringantipd1treatmentinclassicalhodgkinlymphoma |